Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Completed 23Terminated 3Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Thoracic 1

Conditions

Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × nintedanib × Clear all
NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Hoosier Cancer Research Network

Phase 1 Terminated
11 enrolled
Gynecologic

Ovarian Neoplasms

NCT02751385 2019-03-14

Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Boehringer Ingelheim

Phase 1 Terminated
2 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Boehringer Ingelheim

Phase 1 Terminated
2 enrolled 5 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡